	US 11,987,623 B2
	Stabilized antibody compositions
Bernhard Günther, Dossenheim (DE); Dieter Scherer, Laufen (CH); Anthony Pettigrew, Heidelberg (DE); and Gesche Graf, Bensheim (DE)
Assigned to NOVALIQ GMBH, Heidelberg (DE)
Filed by NOVALIQ GMBH, Heidelberg (DE)
Filed on May 14, 2021, as Appl. No. 17/320,693.
Application 16/294,506 is a division of application No. 14/907,254, granted, now 10,273,298, issued on Apr. 30, 2019, previously published as PCT/EP2014/065840, filed on Jul. 23, 2014.
Application 17/320,693 is a continuation of application No. 16/294,506, filed on Mar. 6, 2019, abandoned.
Claims priority of application No. 13177699 (EP), filed on Jul. 23, 2013.
Prior Publication US 2021/0340248 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 39/395 (2013.01); A61K 39/39591 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)]

20 Claims

1. A composition comprising an antigen-binding polypeptide or protein and a liquid vehicle, wherein the liquid vehicle comprises a semifluorinated alkane selected from F4H5, F4H6, F4H8, F6H4, F6H6, F6H8, and F6H10; and wherein the antigen-binding polypeptide or protein is incorporated in the composition such as to form a suspension;

wherein the composition is substantially free of water.